Objective: The objective of this study was to evaluate the prevalence of cardiovascular disease and drug utilization pattern.

Methods: Total 448 patients of cardiovascular disease were randomly selected from outdoor and indoor of General Medicine and Cardiology department of IGIMS, Patna. Prescriptions and bed head ticket of selected patients were analyzed and documented for demographic variables, indication, disease prevalence, co- morbidities and prescribing pattern of the physician.

Results: Majority (48.21%) of patients in age group of 61-90 years were diagnosed with different cardiovascular diseases (CVDs).  Male patients (68%) were diagnosed CVDs more than female patients (32%). This study indicated that hyperlipidaemia (84.82%), hypertension (80.36%) and ischemic heart disease (66.96%) were most frequently diagnosed CVDs and most of the diseases were treated by the combination of two or three drugs. Common drugs prescribed were beta blockers (83%), statins (68%), angiotensin-converting enzymes(ACE) inhibitors (42%), diuretics (40%), calcium channel blockers (37%) and antiplatelets (34%). Diabetes (89.29%), asthma (48.21%) and anaemia (67%) were the comorbidities associated with CVDs.

Conclusion: Hyperlipidaemia, hypertension and ischemic heart disease were the prevalent diseases among CVDs. Statins and antihypertensive were most prescribed drugs. Combinations of drugs were prescribed to the patients for effective therapy. The present study will help the healthcare professionals to optimize the efficient and safe use of cardiovascular drugs.

Keywords: Ischemic heart diseases, Hypertension, Rational, Health professionals.

1. Bergman U. The history of the drug utilization research group in Europe. Pharmacoepidemiol Drug Saf 2006;15:95-8.
2. Taskeen M, AnithaN, Ali SR, Bharath R, Khan AB. A study on rational drug prescribing pattern in geriatric patients in Hyderabad metropolitan. J Drug Delivery 2012;2:109-13.
3. Dukes MNG, World Health O. Drug utilization studies: methods and uses. World Health Organization, Regional Office for Europe Copenhagen; 1993.
4. Al-Junid SM, Ezat WPS, Surianti S. Prescribing patterns and drug cost among cardiovascular patients in Hospital Universiti Kebangsaan Malaysia. Med J Malaysia 2007;62:59-65.
5. Sreedevi K, Rao  JV,  Fareedullah  MD,  Vijayakumar    A study on the prescription pattern of statins in cardiovascular disease. Der Pharm Lett 2011;3:393-6.
6. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in  1990  and  2010:  a  systematic  analysis  for  the  global  burden  of  disease    Lancet 2010;380:2095-128.
7. Muhit MA, Rahman MO, Raihan SZ, Asaduzzaman M, Akbar MA, Sharmin N, et al. Cardiovascular  disease prevalence and prescription patterns at a tertiary level hospital in Bangladesh. J Appl Pharm Sci 2012;2:80-4.
8. Manjula Devi AS, Sriram S, Rajalingam B, Alfet Raju A, Varghese RS, Venkata Phani A. Evaluation of the rationality of fixed dose combinations of cardiovascular drugs in a multispecialty tertiary care hospital in Coimbatore, Tamilnadu, India. Hygeia: J Drugs Med 2012;4:51-8.
9. Khonputsa P, Veerman LJ, Bertram M, Lim SS, Chaiyakunnaphruk N, Vos T. Generalized cost-effectiveness analysis of pharmaceutical interventions for primary prevention of cardiovascular disease in Thailand. The value in Health Regional Issues 2012;1:15-22.
10. Psaty BM, Savage PJ, Tell GS, Polak JF, Hirsch CH, Gardin JM, et al. Temporal patterns of antihypertensive medication use among elderly patients: The Cardiovascular Health Study. JAMA 1993;270:1837-41.
11. Jankovic SM, Dejanovic SMD. Drug utilization trends in clinical hospital center" Kragujevac" from 1997 to 1999. Indian J Pharmacol 2001;33:29-6.
12. National Center for Health S. Health, United States: With special feature on medical technology; 2009.
13. Yusuf SHS, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2004;364:937-52.
14. Bloomer, Lisa Danielle Susan. The Y chromosome in cardiovascular disease. PhD diss. University of Leicester; 2013.
15. Scarborough P, Weissberg P. Trends in coronary heart disease, 1961-2011. British Heart Foundation London; 2011.
16. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update A report from the American heart association. Circulation 2010;121:215-46.
17. JR EMaS. Diabetes mellitus and hyperte-nsion. Hypertension 1992;19:403-18.
18. National High Blood  Pressure  Education  Program  Working  National  high blood  pressure  education  program  working group report on primary of hypertension. Arch Intern Med 1993;153:186-208.
19. Sowers JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000;342:969-70.
20. Everly MJ,  Heaton  PC,  Cluxton  RJ.  Beta-blocker   underuse   in  secondary   prevention   of  myocardial   infarction.   Ann Pharmacother 2004;38:286-93.
21. Esposti LD, Martino MD, Saragoni S, Sgreccia A, Capone A, Buda S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypert-ensive  J Clin Hypertens 2004;6:76-82.

Faiyaz Ahmad Ansari

Assistant Professor, Dept of General Medicine

Indira Gandhi Institute of Medical Sciences, Patna, Bihar

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.